Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.

doi:10.1007/s00277-020-04360-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.

Annals of hematology - 1 Aug 2021

Janusz Kamila, Izquierdo Marta Martín, Cadenas Félix López, Ramos Fernando, Sánchez Jesús María Hernández, Lumbreras Eva, Robledo Cristina, Del Real Javier Sánchez, Caballero Juan Carlos, Collado Rosa, Bernal Teresa, Pedro Carme, Insunza Andrés, de Paz Raquel, Xicoy Blanca, Salido Eduardo, García Joaquín Sánchez, Mínguez Sandra Santos, García Cristina Miguel, Muñoz Ana María Simón, Barba Mercedes Sánchez, Rivas Jesús María Hernández, Abáigar María, Campelo María Díez

Abstract excerpt

SF3B1 is a highly mutated gene in myelodysplastic syndrome (MDS) patients, related to a specific subtype and parameters of good prognosis in MDS without excess blasts. More than 40% of MDS patients carry at least two myeloid-related gene mutations but little is known about the impact of concurrent mutations on the outcome of MDS patients. In applying next-generation sequencing (NGS) with a 117 myeloid gene custom...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dioxygenases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Binding Proteins

Share to DNA (Cytosine-5-)-Methyltransferases

Share to DNA Methyltransferase 3A

Share to Myelodysplastic Syndromes

Share to Phosphoproteins

Share to Proto-Oncogene Proteins

Share to RNA Splicing Factors

Source

Open in PubMed

Identifiers

PMID: 33409621
DOI: 10.1007/s00277-020-04360-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.PMID 33409621Read ↗

Clinical Characteristics and Molecular Profiling of SF3B1-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice.Semantic proximity Read ↗

Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.Semantic proximity Read ↗

Prognostic impact of DTA mutation and co-occurring mutations in patients with myelodysplastic syndrome.Semantic proximity Read ↗

[Clinical Characteristics and Prognosis Analysis of MDS-RS Patients with Wild-Type SF3B1].Semantic proximity Read ↗

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.Semantic proximity Read ↗

Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.Semantic proximity Read ↗

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.Semantic proximity Read ↗

Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome.Semantic proximity Read ↗

[Clinical features of SF3B1 mutation in patients with myelodysplastic syndrome with excess blasts].Semantic proximity Read ↗

Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosisSemantic proximity Read ↗

Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.Semantic proximity Read ↗

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.